GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)
This study will collect safety information on the use of GARDASIL™ in the Philippines.
Papillomavirus Infections
Number of participants with adverse events following any dose of vaccine, At least 30 days following any vaccine dose
This study will collect safety information on the use of GARDASIL™ in the Philippines.